Regentis Biomaterials Ltd. (NYSE American: RGNT) is pressing ahead with the development and commercialization of GelrinC®, its lead product — a cell-free, off-the-shelf hydrogel implant designed to treat cartilage injuries in the knee. Executive Chairman and CEO Dr. Ehud Geller outlined the company's recent progress during an appearance on The BioMedWire Podcast, according to a press release.

GelrinC is already approved for marketing in Europe and is currently being evaluated in a pivotal clinical trial in the United States. Geller said Regentis is working to expand the number of clinical sites participating in the study and aims to complete patient enrollment around year-end. The trial is regarded as a critical step toward potential U.S. regulatory approval. Near-term markers for the program include the addition of participating clinical sites and whether patient enrollment closes on the company's year-end timeline.

According to the company's estimates, the U.S. market encompasses approximately 470,000 cases of cartilage knee repair annually that currently go untreated. Regentis states that no off-the-shelf treatment is available today for these patients, a gap GelrinC is designed to fill by regenerating damaged tissue. The hydrogel is engineered to be eroded and resorbed within the knee, allowing surrounding cells to regenerate cartilage through a controlled and synchronous process.

Beyond the U.S. trial, Regentis is pursuing commercialization in Europe. Geller noted that the company is in discussions with distribution systems and major orthopedic companies to advance market penetration across the region. Such partnerships could accelerate patient access to GelrinC and generate revenue while the U.S. trial continues. The outcome of those discussions is among the developments to watch as the company works to build its European presence.

The regenerative medicine field is expanding rapidly, and Regentis' platform technology — based on synchronized, degradable hydrogel implants — could have applications beyond knee cartilage. While the company's initial focus is orthopedic treatment, the Gelrin platform may be adapted to regenerate other damaged or diseased tissues, including inflamed cartilage and.

Completion of enrollment in the U.S. pivotal study would bring Regentis closer to potential entry into the world's largest healthcare market, while European commercialization efforts could provide early revenue and validate the technology. The company's shares trade on the NYSE American under the ticker RGNT.

Regentis Biomaterials is dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. The latest news and updates relating to RGNT are available in the company's newsroom at

The podcast was produced by BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. More information about BioMedWire can be found at

Source: Citybuzz